Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable BiologicsPRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced it has entered into a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (“EirGenix”) (TWSE: 6589), a global biopharmaceutical development and manufacturing company.
Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO AsiaData showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months
